• No products in the list
FlashDx GBS
21 November 2023

New FlashDx GBS Test: A Key Tool for Protecting Maternal and Infant Health

The GBS Test by FlashDx introduces an improvement in the field of prenatal care and infant safety. Now part of our product offerings, this test addresses the crucial need for early detection of Group B Streptococcus (GBS), a common yet potentially dangerous bacterium during pregnancy and childbirth.

GBS, often harmless in adults, can pose significant risks when transmitted to newborns, potentially leading to serious infections like meningitis, sepsis, or pneumonia. These conditions can be severe and life-threatening, highlighting the importance of early and accurate detection.

The GBS Test utilizes advanced microarray-qPCR technology to precisely identify the presence of GBS in clinical samples. It is designed for use in a clinical setting, making it a valuable tool for healthcare providers in managing prenatal care. The test’s operational simplicity, with its single-use, disposable cartridge system, ensures ease of use while maintaining accuracy and minimizing the risk of contamination.

The introduction of this test into prenatal care routines enables early identification of GBS carriers. This early detection is crucial in planning safer delivery methods to prevent the transmission of the bacterium from mother to child, thus protecting the newborn’s health.

By providing this innovative diagnostic tool, we aim to enhance the safety and well-being of mothers and infants, reducing the risks associated with GBS infections. The GBS Test reflects our commitment to improving healthcare outcomes through advanced diagnostic solutions.


Gerelateerde blogs

Announcement of webinar and new ViennaLab plugins for RealFast™ assays

cfDNA innovations introduced: Join Goffin Molecular Technologies at the 6th Dutch Symposium

New FlashDx GBS Test: A Key Tool for Protecting Maternal and Infant Health